V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160011377 | 160013810 | 0 | 77.4 | Adjuvant (A) | 2020-10-27 | 2020-12-12 | Olaratumab | 02 | N | OLARATUMAB | 100726833 |
| 160011483 | 160013812 | 1.6 | 61.7 | Curative (C) | 2018-09-14 | 2018-11-08 | Venetoclax | N | N | DOXORUBICIN + IFOSFAMIDE | 100140198 |
| 160011501 | 160013813 | 0 | 99.7 | Palliative (P) | 2019-01-14 | 2019-02-01 | null | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100685188 |
| 160011566 | 160013814 | 0 | 65.4 | Curative (C) | 2016-01-08 | 2016-02-23 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | GEMCITABINE | 100790853 |
| 160011782 | 160013815 | 1.8 | 74.7 | null | 2017-09-02 | 2017-12-03 | CARBOPLATIN + ETOPOSIDE | 02 | null | NOT MATCHED | 101612656 |
| 160011962 | 160013817 | null | 74.7 | Neo-adjuvant (N) | 2018-01-10 | 2018-04-10 | Olaratumab | 02 | N | PROMISE-MESO TRIAL | 100667890 |
| 160012068 | 160013818 | 1.63 | 67.3 | Neo-adjuvant (N) | 2019-05-27 | 2019-10-29 | Ipilimumab | 02 | N | NB HRNBL-1 BUMEL MAT | 101598329 |
| 160012281 | 160013820 | null | 76.4 | Curative (C) | 2018-12-12 | 2018-12-17 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | IVA | 101765114 |
| 160012366 | 160013821 | 1.74 | 56.1 | Curative (C) | 2017-04-10 | 2017-11-16 | Cyclophosphamide oral | 02 | N | ERIBULIN | 100358644 |
| 160012455 | 160013822 | 0 | 60.7 | null | 2017-08-23 | 2017-08-23 | Dacarbazine | 01 | null | STS RHABDO RMS 2005 | 100067373 |
| 160012688 | 160013824 | 1.76 | 57.6 | Curative (C) | 2019-07-05 | 2019-07-05 | Cisplatin + Doxorubicin | 02 | N | DACTINOMYCIN + CYCLO + VINCRISTINE | 100989511 |
| 160012721 | 160013825 | 1.8 | 56.3 | null | null | 2014-10-13 | EW EuroEwing 2012 Arm B VDC | 02 | null | RMS 2005 TRIAL | 101777446 |
| 160012758 | 160013826 | 1.85 | 41.4 | Palliative (P) | 2015-06-30 | 2015-07-14 | STS Rhabdomyosarcoma RMS 2005 VA | 02 | N | PEMBROLIZUMAB | 100056677 |
| 160012860 | 160013827 | 1.72 | 66.5 | Palliative (P) | 2018-12-28 | 2019-05-12 | EW EuroEwing 2012 Arm B VC | 01 | N | IFOSFAMIDE | 100453526 |
| 160012971 | 160013828 | 0 | 59.8 | Curative (C) | 2019-05-05 | 2019-08-27 | Trial Unspecified | 99 | Y | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 101093513 |
| 160013122 | 160013829 | 1.85 | 65 | Palliative (P) | 2019-10-15 | 2019-10-21 | IVA | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100659814 |
| 160013221 | 160013830 | 1.79 | 86.2 | Palliative (P) | 2019-10-27 | 2019-11-09 | EW Rel rEECur Irinotecan/Temozolomide | 02 | N | NB HRNBL-1 BUMEL MAT | 101369553 |
| 160013461 | 160013834 | 1.79 | 14.1 | Palliative (P) | 2018-10-30 | 2018-10-30 | CAPECITABINE + OXALIPLATIN | 02 | N | IVA | 101452805 |
| 160013479 | 160013835 | 0 | 19.9 | null | 2020-02-16 | 2020-08-02 | EW EuroEwing 2012 Arm B VC | 02 | null | BORTEZOMIB | 100037693 |
| 160013663 | 160013836 | 1.82 | 124.5 | null | 2022-01-09 | 2022-01-15 | STS Rhabdo RMS 2005 | null | null | OLARATUMAB | 101502334 |
| 160013780 | 160013837 | 1.88 | 0 | Neo-adjuvant (N) | 2018-04-24 | 2018-04-30 | Cyclophosphamide oral | N | N | NIRAPARIB | 100980541 |
| 160013823 | 160013838 | 1.65 | 55 | null | 2018-10-05 | 2018-10-09 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100545757 |
| 160013993 | 160013839 | 1.67 | 14.45 | Palliative (P) | 2019-06-15 | 2019-06-22 | Rucaparib | null | Y | DACARBAZINE | 101743858 |
| 160014086 | 160013840 | 0 | 59 | null | null | 2018-05-07 | STS Rhabdomyosarcoma RMS 2005 IVA | 01 | null | GEMCITABINE | 100998920 |
| 160014131 | 160013841 | 1.71 | 52 | Palliative (P) | 2019-02-14 | 2019-02-22 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | NB HRNBL-1 ISOTRETINOIN | 101216764 |
| 160014432 | 160013845 | 0 | 112 | 03 | 2018-04-15 | 2018-05-13 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | IFOSFAMIDE | 101285374 |
| 160014507 | 160013846 | 1.58 | 78.6 | Palliative (P) | null | 2018-03-14 | VINCRISTINE | 02 | N | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 100233488 |
| 160014575 | 160013847 | 0 | 94 | null | 2017-11-03 | 2017-11-23 | ETOP 13-18 BEAT-meso Trial | 02 | null | CABOZANTINIB | 100932501 |
| 160014624 | 160013848 | 1.66 | 60.3 | null | 2016-07-23 | 2016-07-23 | ETOPOSIDE + IFOSFAMIDE | 02 | null | NB REL GD2CH14.18/CHO, IL-2 ISOTRET | 100917785 |
| 160014722 | 160013849 | 0 | 74.9 | Curative (C) | 2018-11-28 | 2018-12-06 | Trastuzumab 21 day maintenance | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100901395 |
| 160014891 | 160013850 | 1.59 | 109.9 | null | 2017-09-29 | 2017-09-29 | Ifosfamide | 02 | null | IFOSFAMIDE | 101812067 |
| 160015058 | 160013851 | 1.63 | 99.7 | Disease modification (D) | 2018-07-20 | 2018-07-21 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | STS RHABDOMYOSARCOMA RELAPSE IRINOTECAN/ TEMOZOLOMIDE/ VINCRISTINE | 101134529 |
| 160015356 | 160013852 | 0 | 75 | 02 | 2018-11-29 | 2018-12-12 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 101248320 |
| 160015366 | 160013853 | 1.82 | 45 | Curative (C) | 2018-09-19 | 2019-05-01 | EW EuroEwing 2012 Arm B VC | N | N | GEMCITABINE | 101057345 |
| 160015376 | 160013854 | 0 | 94 | null | 2019-04-19 | 2019-04-19 | ETOP 13-18 BEAT-meso Trial | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101742479 |
| 160015547 | 160013857 | 1.8 | 32.2 | null | 2018-07-13 | 2018-09-27 | NB HRNBL-1 Isotretinoin | null | null | ETOPOSIDE | 101260596 |
| 160015559 | 160013858 | 1.71 | 84 | null | null | 2019-08-28 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | null | CARBOPLATIN + ETOPOSIDE | 100215341 |
| 160015614 | 160013859 | 1.86 | 61.3 | Palliative (P) | null | 2014-08-07 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | TOPOTECAN | 100093550 |
| 160015644 | 160013860 | 1.15 | 13.05 | Palliative (P) | null | null | NEMO TRIAL | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 101691294 |
| 160015907 | 160013861 | 1.62 | 71.65 | null | 2017-05-10 | 2017-05-28 | PEMBROLIZUMAB | 01 | null | RUCAPARIB | 101523408 |
| 160016294 | 160013863 | 1.64 | 83.5 | null | 2018-08-09 | 2018-08-09 | Pemetrexed | 02 | null | IVA | 100012257 |
| 160016351 | 160013864 | 1.63 | 46.2 | Palliative (P) | null | 2013-07-01 | Dacarbazine | N | N | ETOPOSIDE | 100433377 |
| 160016392 | 160013865 | 1.77 | 100 | Palliative (P) | 2018-04-29 | 2018-05-03 | ATOMIC-MESO TRIAL | 02 | N | CARBOPLATIN + VINORELBINE | 101645454 |
| 160016734 | 160013867 | 1.84 | 68 | null | 2018-10-04 | 2018-10-04 | CARBOPLATIN + GEMCITABINE | 02 | N | EW EUROEWING 2012 ARM B IE | 100068510 |
| 160016886 | 160013868 | 1.61 | 52.3 | Curative (C) | 2017-09-11 | 2017-10-01 | Cyclophosphamide oral | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101764625 |
| 160017049 | 160013869 | 1.67 | 94.7 | Curative (C) | 2018-01-20 | 2018-02-09 | EW EuroEwing 2012 Arm B VDC | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101696667 |
| 160017106 | 160013871 | 1.5 | 84.2 | Palliative (P) | 2018-10-20 | 2018-10-25 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 01 | N | ETOP 13-18 BEAT-MESO TRIAL | 100451101 |
| 160017273 | 160013872 | 1.05 | 88.5 | null | 2017-09-04 | 2018-06-25 | BEP 5 Day | 02 | null | PROMISE-MESO TRIAL | 100423693 |
| 160017330 | 160013873 | 1.78 | 92.9 | Curative (C) | 2019-01-17 | 2019-01-18 | Dacarbazine | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101791368 |
| 160017345 | 160013875 | 1.63 | 17.1 | null | 2017-04-16 | 2017-05-13 | Trial Unspecified | null | null | DOXORUBICIN + IFOSFAMIDE | 101752473 |